Pyrrolidinopyrazole-substituted oximes having the formula ##STR1## are disclosed wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and a are as described in the claims for the treatment of atherosclerosis and hypercholesterolemia.
本文披露了具有以下式子的
吡咯烷基
吡唑取代
肟类化合物:##STR1## 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和a的定义如权利要求书中所述,适用于动脉硬化和高
胆固醇血症的治疗。